Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018

Euro Surveill. 2018 Apr;23(16):18-00158. doi: 10.2807/1560-7917.ES.2018.23.16.18-00158.

Abstract

The annual incidence rate of serogroup W invasive meningococcal disease in the Netherlands increased from < 0.05/100,000 (n < 10) before 2015 to 0.5/100,000 (n = 80) in 2017. Most isolates (94%) belong to clonal complex 11. The incidence rate is highest among < 5 year-olds and 15-24 year-olds. The case fatality rate was 12% (17/138) in 2015-2017. From May 2018, MenACWY vaccination replaces MenC vaccination at age 14 months and from October 2018, 13-14 year-olds are offered MenACWY vaccination.

Keywords: Neisseria meninigitidis; bacterial infections; meningococcal disease; public health policy; vaccine-preventable diseases; vaccines and immunisation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Female
  • Humans
  • Immunization, Secondary
  • Incidence
  • Male
  • Meningococcal Infections / epidemiology
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / administration & dosage
  • Meningococcal Vaccines / immunology*
  • Middle Aged
  • Neisseria meningitidis, Serogroup W-135 / immunology
  • Neisseria meningitidis, Serogroup W-135 / isolation & purification*
  • Netherlands / epidemiology
  • Serogroup
  • Vaccination / methods
  • Vaccines, Conjugate
  • Young Adult

Substances

  • MenACWY
  • Meningococcal Vaccines
  • Vaccines, Conjugate